GlaxoSmithKline plc (LON:GSK) insider Victoria Whyte purchased 9 shares of the stock in a transaction on Tuesday, October 10th. The stock was acquired at an average cost of GBX 1,518 ($19.96) per share, for a total transaction of £136.62 ($179.62).

Shares of GlaxoSmithKline plc (GSK) traded up 0.03% during mid-day trading on Wednesday, hitting GBX 1516.00. The stock had a trading volume of 2,084,248 shares. The firm’s market capitalization is GBX 74.10 billion. The stock’s 50-day moving average is GBX 1,499.71 and its 200-day moving average is GBX 1,587.03. GlaxoSmithKline plc has a 1-year low of GBX 1,444.00 and a 1-year high of GBX 1,724.50.

The business also recently disclosed a dividend, which will be paid on Thursday, October 12th. Investors of record on Thursday, August 10th will be paid a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.

ILLEGAL ACTIVITY NOTICE: “Insider Buying: GlaxoSmithKline plc (GSK) Insider Purchases 9 Shares of Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/11/insider-buying-glaxosmithkline-plc-gsk-insider-purchases-9-shares-of-stock.html.

Several equities research analysts have issued reports on GSK shares. Liberum Capital reissued a “buy” rating and issued a GBX 1,900 ($24.98) price target on shares of GlaxoSmithKline plc in a report on Wednesday, June 14th. Jefferies Group LLC boosted their price target on shares of GlaxoSmithKline plc from GBX 1,800 ($23.67) to GBX 1,900 ($24.98) and gave the company a “buy” rating in a report on Friday, June 16th. Deutsche Bank AG reissued a “hold” rating and issued a GBX 1,720 ($22.61) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th. J P Morgan Chase & Co reissued a “neutral” rating and issued a GBX 1,750 ($23.01) price target on shares of GlaxoSmithKline plc in a report on Friday, June 30th. Finally, Barclays PLC reissued an “equal weight” rating and issued a GBX 1,550 ($20.38) price target on shares of GlaxoSmithKline plc in a report on Monday, July 3rd. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have given a buy rating to the company’s stock. GlaxoSmithKline plc has an average rating of “Hold” and a consensus price target of GBX 1,689.48 ($22.21).

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.